Synaptive Medical has collaborated with Colorado State University’s (CSU’s) Flint Animal Cancer Centre to develop a new intraoperative imaging and sensing technology for detection and treatment of brain tumours.
CSU neurology and neurosurgery associate professor Dr Rebecca Packer utilised Synaptive’s Raman spectroscopy research system to assess the clinical biomarkers with potential for use in surgical resection of tumours.
With a focus on new brain tumour therapies, Dr Packer’s research aims to create precise and less invasive neurosurgical techniques and therapies to treat the tumours.
The research also includes improvement of intraoperative imaging for accurate detection and resection of tumours during surgery.
Dr Packer said: “We expect that, ultimately, this technology will make the surgical resection of brain tumours safer and more accurate, but given the advancements in tumour vaccines and immunotherapies, it is reasonable to speculate that one day a device might even allow us to obtain a diagnosis and determine optimal patient-specific treatments without the need for invasive surgery.”
Synaptive will work on interconnection and optimisation of the flow of imaging and non-imaging data as well as its integration into current surgical technologies.
Synaptive Medical president and co-founder Cameron Piron said: “Novel sensing technologies would support a surgeon when she is performing a procedure and when rapid clinical decisions need to be made.
“The Flint Animal Cancer Centre is among the best in the world for the prevention, diagnosis and treatment of cancer in pet animals, and this is a natural collaboration for us to advance both veterinary and human neurosurgery.”
CSU research will initially include confirmation of the specific spectral fingerprint of different types of brain tumours and matching the fingerprint with the microscopic appearance of the tumour and surrounding normal tissue.
Image: Dr Rebecca Packer, neurology and neurosurgery associate professor at CSU. Photo: courtesy of Business Wire.